Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Down 43.7% in August

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 178,126 shares, a drop of 43.7% from the August 15th total of 316,392 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average trading volume of 691,114 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Ratings Changes

Several research firms have recently commented on MBRX. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Wall Street Zen upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, HC Wainwright cut their price target on Moleculin Biotech to $3.00 and set a “buy” rating for the company in a report on Friday, August 28th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Moleculin Biotech Stock Up 5.4%

NASDAQ:MBRX traded up $0.04 during trading hours on Thursday, hitting $0.78. 304,420 shares of the stock traded hands, compared to its average volume of 583,852. Moleculin Biotech has a 1 year low of $0.16 and a 1 year high of $15.75. The company has a market cap of $15.19 million, a price-to-earnings ratio of -0.11 and a beta of 1.92. The stock has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.97.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. Equities analysts forecast that Moleculin Biotech will post -2.37 earnings per share for the current fiscal year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.